NEW YORK (GenomeWeb News) — Diagnostics technologies developer Avacta Group and the University of Liverpool will collaborate to develop integrated microarray and mass spectrometry tools for use in detecting biomarkers and discovering new drug targets.

Wetherby, UK-based Avacta said today the partners will combine the firm's engineered affinity reagent microarrays, which it calls Affimer microarrays, and reagents with mass spectrometry tools developed by University of Liverpool Professor Rob Beynon.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.